Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778368) titled 'A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai East Hospital
Condition:
Oral Squamous Cell Carcinoma (OSCC)
Intervention:
Drug: Sacituzumab Govitecan OR Sacituzumab Tirumotecan in Combination with Toripalimab
Procedure: Radical Surgery for OSCC
Radiation: Radiation Therapy
Recruitment Status: Not recruiting
Phase...